Pykus Therapeutics is a Cambridge-based company founded in 2016 with the aim of enhancing the patient care experience following retinal surgery. Their lead product, PYK-1107, is a groundbreaking biodegradable retinal sealant that eliminates the need for facedown positioning or blurred vision during post-operative recovery.
With over 1.8 million retina surgeries performed annually, Pykus Therapeutics recognizes the challenges faced by patients undergoing these procedures. PYK-1107, a novel in situ cross-linking biodegradable hydrogel, is administered in the operating room and allows the retina to heal without the need for repeat surgery, air travel restrictions, or other post-operative inconveniences.
Generated from the website